A federal advisory committee is meeting today to discuss the risks and benefits of using MDMA as a treatment for post-traumatic stress disorder (PTSD). MDMA, commonly known as ecstasy, is currently classified as a schedule I drug. This would be the first time that the FDA’s advisers have considered a psychedelic drug for medical use. About 5% of adults in the United States experience PTSD, but current treatment options are limited. Lykos Therapeutics has conducted promising clinical trials using MDMA in combination with therapy to treat PTSD. The FDA has acknowledged the potential benefits but also raised concerns about the data and safety. The advisory committee meeting will provide an opportunity to gather more information. The use of psychedelics as therapeutics is gaining interest and support, but experts caution about the need for careful study and monitoring. The outcome of the FDA’s decision could have significant implications for future treatments.
